TABLE 5.
Key genomic alterations in napsin A-positive large cell neuroendocrine carcinomas.
| Alterations typical of NSCLC: KRAS, STK11, other | Alteration typical of SCLC: RB1 mutation/loss |
Molecular method | |
|---|---|---|---|
| Case 1 | Negative | na# | Sequenom Genotyping + Fragment analysis |
| Case 2 | na | na | |
| Case 3 | na | na | |
| Case 4 | KRAS G12V | na# | Sequenom Genotyping + Fragment analysis |
| Case 5 | ERBB2 (HER2) insertion | na# | Sequenom Genotyping + Fragment analysis |
| Case 6 | na | na | |
| Case 7 | KRAS G12C | na# | Sequenom Genotyping + Fragment analysis |
| Case 8 | Negative | na# | Sequenom Genotyping + Fragment analysis |
| Case 9 (ID 42)* | STK11 X97_splice | absent | NGS – MSK-IMPACT |
| Case 10 (ID 49)* | KRAS G12C + STK11 H168R | absent | NGS – MSK-IMPACT |
| Case 11 (ID 28)* | STK11 C278fs | absent | NGS – MSK-IMPACT |
| Case 12 (ID 32)* | KRAS G12C + STK11 V320fs | absent | NGS – MSK-IMPACT |
| Case 13 (ID 59)* | KRAS G12D | absent | NGS – MSK-IMPACT |
| Case 14 (ID 38)* | KRAS G12C | absent | NGS – MSK-IMPACT |
| Case 15 (ID 40)* | STK11 H107L | absent | NGS – MSK-IMPACT |
| Case 16 (ID 39)* | KRAS Q61L | RB1 V434fs | NGS – MSK-IMPACT |
| Case 17 (ID 64)* | STK11 E165* | absent | NGS – MSK-IMPACT |
NSCLC – non small cell lung carcinoma, NGS – next generation sequencing, MSK-IMPACT - Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets platform, na – not available (molecular testing not performed), na# – Sequenom assay does not include RB1 gene testing